Compliance Rate

Compliance Rate 100.0%
Compliant submissions 1
Incompliant submissions 0
Total trials 1

My Organizations' Clinical Trials

Showing 1600 of 2051 entries
View as:

Study of Vaniprevir Plus PegIntron®/Ribavirin in Japanese Participants With Chronic Hepatitis C Who Relapsed After Treatment (MK-7009-044)

Phase: N/A Priority: Normal
NCT ID: NCT01405937 Org: User:
Start: 08/29/11 End: 03/12/13 Due: 03/12/14

Dose-Finding Safety and Efficacy Trial of Org 50081 (Esmirtazapine) in the Treatment of Vasomotor Symptoms (177001/P06472/MK-8265-013)

Phase: N/A Priority: Normal
NCT ID: NCT00535288 Org: User:
Start: 09/15/04 End: 01/15/06 Due: 01/15/07

Study of the Efficacy and Safety of SCH 619734 in Subjects With Chronic Cough From an Unknown Cause (Study P04888)

Phase: N/A Priority: Normal
NCT ID: NCT00506545 Org: User:
Start: 01/31/07 End: 10/31/07 Due: 10/31/08

A Study to Evaluate the Effects of Laropiprant on the Antiplatelet Effects of Clopidogrel and Aspirin in Combination (MK-0524A-114)(COMPLETED)

Phase: N/A Priority: Normal
NCT ID: NCT01012219 Org: User:
Start: 11/30/09 End: 04/30/10 Due: 04/30/11

Immunogenicity and Safety of Concomitant and Non-Concomitant Administration of RotaTeq® (V260) and Inactivated Poliomyelitis Vaccine in Healthy Chinese Infants (V260-074)

Phase: N/A Priority: Normal
NCT ID: NCT04481191 Org: User:
Start: 08/25/20 End: 05/08/21 Due: 05/08/22

Assessment of the Fungal Infection Incidence Across Canada for High Risk Participants With Hematological Disease (P07501)

Phase: N/A Priority: Normal
NCT ID: NCT01254318 Org: User:
Start: 03/31/13 End: 11/30/14 Due: 11/30/15

A Study to Assess the Safety, Tolerability and Glucose-Lowering Efficacy of MK-0893 in Participants With Type 2 Diabetes Mellitus (MK-0893-005)

Phase: N/A Priority: Normal
NCT ID: NCT02004886 Org: User:
Start: 08/11/06 End: 02/07/07 Due: 02/07/08

A Study of Gefapixant (MK-7264) in Japanese Adult Participants With Refractory or Unexplained Chronic Cough (MK-7264-038)

Phase: N/A Priority: Normal
NCT ID: NCT03696108 Org: User:
Start: 10/31/18 End: 10/07/20 Due: 10/07/21

MK-0431 Early Phase II Double-blind Study - Type 2 Diabetes Mellitus (0431-043)

Phase: N/A Priority: Normal
NCT ID: NCT00371007 Org: User:
Start: 06/01/04 End: 04/25/05 Due: 04/25/06

A Study of MK-1084 With Midazolam and Digoxin in Healthy Participants (MK-1084-009)

Phase: N/A Priority: Normal
NCT ID: NCT06575933 Org: User:
Start: 09/03/24 End: 10/28/24 Due: 10/28/25

Safety and Pharmacokinetics of Ceftolozane/Tazobactam in Pediatric Participants With Nosocomial Pneumonia (MK-7625A-036)

Phase: N/A Priority: Normal
NCT ID: NCT04223752 Org: User:
Start: 04/17/20 End: 09/14/24 Due: 09/14/25

A Study to Evaluate the Safety, Immune Response, and Efficacy of Gardasil (V501, qHPV) in Mid-Adult Women (V501-019)

Phase: N/A Priority: Normal
NCT ID: NCT00090220 Org: User:
Start: 06/16/04 End: 11/12/15 Due: 11/12/16

Efficacy & Safety of Infliximab Monotherapy Vs Combination Therapy Vs AZA Monotherapy in Ulcerative Colitis (Part 1) Maintenance Vs Intermittent Therapy for Maintaining Remission (Part 2)(Study P04807)

Phase: N/A Priority: Normal
NCT ID: NCT00537316 Org: User:
Start: 07/31/07 End: 02/28/10 Due: 02/28/11

A Study of the Effects of Itraconazole on the Plasma Levels of Nemtabrutinib (MK-1026-013)

Phase: N/A Priority: Normal
NCT ID: NCT06688045 Org: User:
Start: 10/30/23 End: 01/06/24 Due: 01/06/25

Study of Olaparib Plus Pembrolizumab Versus Chemotherapy Plus Pembrolizumab After Induction With First-Line Chemotherapy Plus Pembrolizumab in Triple Negative Breast Cancer (TNBC) (MK-7339-009/KEYLYNK-009)

Phase: N/A Priority: Normal
NCT ID: NCT04191135 Org: User:
Start: 12/19/19 End: 11/18/25 Due: 11/18/26

Study A - MK0767 Monotherapy Study

Phase: N/A Priority: Normal
NCT ID: NCT00543517 Org: User:
Start: 02/28/03 End: 11/30/03 Due: 11/30/04

A Study to Evaluate the Safety and Efficacy of an Investigational Drug in the Treatment of Postoperative Dental Pain (MK-2295-005)

Phase: N/A Priority: Normal
NCT ID: NCT00387140 Org: User:
Start: 10/31/06 End: 05/31/07 Due: 05/31/08

A Study on the Effect of Kidney Disease on a Diabetes Medication (0431-008)

Phase: N/A Priority: Normal
NCT ID: NCT00418366 Org: User:
Start: 01/31/03 End: 03/31/03 Due: 03/31/04

Pharmacokinetics, Safety, and Tolerability of Ertugliflozin (MK-8835/PF-04971729) in Participants With Hepatic Impairment and in Healthy Participants (MK-8835-014)

Phase: N/A Priority: Normal
NCT ID: NCT02115347 Org: User:
Start: 09/19/14 End: 01/19/15 Due: 01/19/16

Safety and Tolerability of Pembrolizumab (MK-3475) + Pegylated Interferon Alfa-2b and Pembrolizumab+ Ipilimumab in Participants With Advanced Melanoma or Renal Cell Carcinoma (MK-3475-029/KEYNOTE-29)

Phase: N/A Priority: Normal
NCT ID: NCT02089685 Org: User:
Start: 03/17/14 End: 04/01/21 Due: 04/01/22

Boceprevir Treatment in Participants With Chronic Hepatitis C Genotype 1 Deemed Nonresponders to Peginterferon/Ribavirin (P05514)

Phase: N/A Priority: Normal
NCT ID: NCT00910624 Org: User:
Start: 06/22/09 End: 12/07/12 Due: 12/07/13

Characterization of Baseline Biomarker Variability in Participants With Hepatocellular Carcinoma (MK-0000-215)

Phase: N/A Priority: Normal
NCT ID: NCT01521780 Org: User:
Start: 04/30/12 End: 11/30/12 Due: 11/30/13

A Safety and Tolerability Study of Denufosol in 2-4 Year Olds

Phase: N/A Priority: Normal
NCT ID: NCT01181622 Org: User:
Start: 08/31/10 End: 10/31/10 Due: 10/31/11

A Study of MK0364 in Obese Patients (0364-014)

Phase: N/A Priority: Normal
NCT ID: NCT00131391 Org: User:
Start: 07/31/05 End: 12/31/08 Due: 12/31/09

Doravirine (DOR) in Human Immunodeficiency Virus (HIV)-Infected Children Ages 4 Weeks to <12 Years and <45 kg (MK-1439-066)

Phase: N/A Priority: Normal
NCT ID: NCT04375800 Org: User:
Start: 02/03/21 End: 04/11/34 Due: 04/11/35